Mesenchymal Stem Cell Therapy for Cardiac Repair
Mesenchymal Stem Cell Therapy for Cardiac Repair
复制标题
DOI：
10.1007/978-1-60761-705-1_5
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Hare, Joshua M.
中科院分区：
文献类型：
--
作者：
Boyle, Andrew J.;McNiece, Ian K.;Hare, Joshua M.
用于修复受损心脏组织的干细胞疗法是改善越来越多心力衰竭患者健康的一个有吸引力的选择。间充质干细胞（MSC）具有独特的特性，可能使它们成为比其他细胞类型更好的心脏修复选择。与其他成体干细胞不同，它们似乎逃脱了免疫系统的同种异体识别，并且具有免疫调节特性，因此可以考虑将它们用作同种异体细胞治疗产品。间充质干细胞治疗的临床前和早期临床经验数量庞大且不断增长，这些经验在实现干细胞治疗修复受损心脏组织的潜力方面显示出巨大的希望。本综述讨论了 MSC 治疗的作用机制，并总结了该领域的现有文献。
Stem cell therapy for repair of damaged cardiac tissue is an attractive option to improve the health of the growing number of heart failure patients. Mesenchymal stem cells (MSCs) possess unique properties that may make them a better option for cardiac repair than other cell types. Unlike other adult stem cells, they appear to escape allorecognition by the immune system and they have immune-modulating properties, thus making it possible to consider them for use as an allogeneic cell therapy product. There is a large and growing body of preclinical and early clinical experience with MSC therapy that shows great promise in realizing the potential of stem cell therapy to effect repair of damaged cardiac tissue. This review discusses the mechanism of action of MSC therapy and summarizes the current literature in the field.